Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients

Transplant Infectious Disease

Volumn 18, Issue 2, 2016, Pages 216-226

  Damlaj, Moussab ^a   Bartoo, G ^a   Cartin Ceba, R ^a   Gijima, D ^a   Alkhateeb, H B ^a   Merten, J ^a   Hashmi, S ^a   Litzow, M ^a   Gastineau, D ^a   Hogan, W ^a   Patnaik, M M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allogeneic stem cell transplant; Bronchiolitis obliterans; Corticosteroids; Respiratory syncytial virus

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; RIBAVIRIN; ANTIVIRUS AGENT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CARBON MONOXIDE DIFFUSION CAPACITY; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HOSPITAL ADMISSION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INTENSIVE CARE UNIT; LACTIC ACIDOSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TIME TO TREATMENT; UPPER RESPIRATORY TRACT INFECTION; VIRUS ISOLATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; COMBINATION DRUG THERAPY; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RIBAVIRIN; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962978231     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12513     Document Type: Article

References (28)

1. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006; 193 (12): 1619-1625.
2. Lehners N, Schnitzler P, Geis S, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant 2013; 48 (12): 1548-1553.
3. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001; 7 (Suppl): 5S-7S.
4. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014; 123 (21): 3263-3268.
5. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209 (8): 1195-1204.
6. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant 2013; 19 (8): 1220-1226.
7. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 2009; 44 (8): 453-455.
8. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184 (3): 350-354.
9. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46 (3): 402-412.
10. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6: 135.
11. Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013; 19 (4): 589-596.
12. Carter MJ. A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol 2007; 56 (Pt 7): 875-883.
13. Patel H, Platt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004; 3: CD004878.
14. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics 2000; 105 (4): E44.
15. Davison C, Ventre KM, Luchetti M, Randolph AG. Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis. Pediatr Crit Care Med 2004; 5 (5): 482-489.
16. van Woensel JB, Vyas H; STAR Trial Group. Dexamethasone in children mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus: a randomized controlled trial. Crit Care Med 2011; 39 (7): 1779-1783.
17. Boudreault AA, Xie H, Leisenring W, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant 2011; 17 (7): 979-986.
18. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11 (12): 945-956.
19. Hachem RR, Chakinala MM, Yusen RD, et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med 2004; 169 (4): 468-472.
20. Lama VN, Murray S, Mumford JA, et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med 2005; 172 (3): 379-383.
21. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117 (10): 2755-2763.
22. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29 (4): 321-327.
23. Marcelin JR, Wilson JW, Razonable RR; Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014; 16 (2): 242-250.
24. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15 (10): 1143-1238.
25. Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child 2000; 82 (2): 126-130.
26. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165 (6): 987-993.
27. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19 (9): 905-908.
28. Abedin S, Yanik GA, Braun T, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant 2015; 21 (6): 1127-1131.